On March 16, 2026, Hepion Pharmaceuticals, Inc. disclosed in an 8-K filing that Dr. Kaouthar Lbiati has resigned as Chief Executive Officer for personal reasons, effective immediately. The Board of Directors has appointed Gary Stetz as the interim Chief Executive Officer and director. Additionally, Vincent LoPriore has been appointed as Executive Chairman, while Sireesh Appajosyula and Chase LoPriore have been appointed as directors. This leadership change comes at a critical time for the company, which is focused on advancing its clinical programs and enhancing shareholder value. The Board confirmed that there are no arrangements or understandings between the newly appointed officers and any other person regarding their selection, and there is no family relationship between them and any of the company's other directors or executive officers. The company continues to operate from its principal executive offices located at 34 Shrewsbury Ave., Suite 1D, Red Bank, NJ 07701.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.